Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Shares Outstanding (Diluted Average) (2019 - 2025)

Sangamo Therapeutics has reported Shares Outstanding (Diluted Average) over the past 7 years, most recently at $280.2 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $280.2 million for Q4 2025, up 38.92% from a year ago — trailing twelve months through Dec 2025 was $280.2 million (up 38.92% YoY), and the annual figure for FY2025 was $280.2 million, up 38.92%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $280.2 million at Sangamo Therapeutics, up from $260.8 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for SGMO hit a ceiling of $280.2 million in Q4 2025 and a floor of $143.1 million in Q1 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $172.9 million (2023), compared with a mean of $184.6 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): increased 2.17% in 2022 and later surged 38.92% in 2025.
  • Sangamo Therapeutics' Shares Outstanding (Diluted Average) stood at $144.6 million in 2021, then increased by 6.76% to $154.3 million in 2022, then increased by 13.02% to $174.4 million in 2023, then rose by 15.62% to $201.7 million in 2024, then surged by 38.92% to $280.2 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $280.2 million (Q4 2025), $260.8 million (Q3 2025), and $257.0 million (Q2 2025) per Business Quant data.